To help ensure the highest level of patient safety and research quality, the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio (UTHSCSA) Protocol Review Committee (PRC) is charged with the responsibility for internal oversight of the scientific and research aspects of all cancer clinical trials at the CTRC at UTHSCSA. The PRC helps to ensure that the Cancer Center's Shared Resources are engaged appropriately to facilitate the best possible study conduct and to maximize the overall scientific productivity of the Cancer Center. The primary PRC function is to review all studies for scienfific merit, to ensure prioritizafion of protocols according to P30 scienfific priorifies, and to monitor study progress for all cancer-related prevenfion and therapeufic clinical research protocols. The Chair of the PRC reports to the P30 Deputy Director. The P30 Office of Research Administrafion (ORA) is a Cancer Center shared resource which provides support to the PRC. The funcfion of the PRC is complementary to that of the UTHSCSA Insfitufional Review Board (IRB), which focuses on the protecfion of human subjects. All stipulafions identified by the PRC must be resolved prior to IRB submission. PRC funcfions do not duplicate or overiap with the responsibilifies of the IRB, nor does the PRC perform either auditing or data and safety monitoring functions which are performed in the CTRC by the ORA and the Data Safety and Monitoring Committee (DSMC) respecfively. The PRC is responsible for pre-acfivation and study continuafion activities related to scientific areas of research. All cancer-related studies involving the use of human subjects require the initial approval of this PRC prior to submission to the UTHSCSA IRB. The PRC has the authority to open protocols (with IRB approval) that demonstrate scientific merit and that meet the priorities of the P30. The PRC can close protocols that do not show sufficient scienfific progress or accrual. All studies, at time of inifial review are assigned a priority of audit level score (PALS) in a joint process between the PRC and DSMC. The Data Safety Officer (DSO), who is a member of both the PRC and DSMC, coordinates this process. A study PALS is then entered into the IDEAS database by the DSO. This score is used to determine the trial's overall likelihood of being audited by the DSO and the audit team. Approval of a protocol by PRC is a fundamental requirement, as is IRB approval, to allow performance of a cancer-related protocol by CTRC at UTHSCSA members within the affiliated institutions of the CTRC at UTHSCSA.

Public Health Relevance

The PRC is crifically important to the Cancer Center's research because of its pivotal role in ensuring that all new protocols opened at the CTRC at UTHSCSA are scientifically sound and are prioritized in terms of Shared Resource ufilizafion which facilitates best possible study conduct and maximizes the overall scientific producfivity of the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-17
Application #
7944796
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-08-03
Project End
2012-07-31
Budget Start
2009-08-03
Budget End
2010-07-31
Support Year
17
Fiscal Year
2009
Total Cost
$23,084
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Chalela, Patricia; Muñoz, Edgar; Gallion, Kipling J et al. (2018) Empowering Latina breast cancer patients to make informed decisions about clinical trials: a pilot study. Transl Behav Med 8:439-449
Chalela, P; Munoz, E; Inupakutika, D et al. (2018) Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. Contemp Clin Trials Commun 12:109-115
Weiner, Marc; Gelfond, Jon; Johnson-Pais, Teresa L et al. (2018) Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother 62:
Liu, Jinyou; Sareddy, Gangadhara R; Zhou, Mei et al. (2018) Differential Effects of Estrogen Receptor ? Isoforms on Glioblastoma Progression. Cancer Res 78:3176-3189
Chakravarthy, Divya; Muñoz, Amanda R; Su, Angel et al. (2018) Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1. Cancer Lett 419:103-115
Van Skike, Candice E; Jahrling, Jordan B; Olson, Angela B et al. (2018) Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol 314:H693-H703
Cooney, Jeffrey D; Lin, An-Ping; Jiang, Daifeng et al. (2018) Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K? in Mature B-cell Malignancies. Clin Cancer Res 24:1103-1113
Zhu, Haiyan; Gu, Xiang; Xia, Lu et al. (2018) A Novel TGF? Trap Blocks Chemotherapeutics-Induced TGF?1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers. Clin Cancer Res 24:2780-2793
Bandyopadhyay, Abhik; Favours, Edward; Phelps, Doris A et al. (2018) Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer 65:
Azpurua, Jorge; Mahoney, Rebekah E; Eaton, Benjamin A (2018) Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell 17:

Showing the most recent 10 out of 989 publications